Board of Directors
Mr. Anurag Bagaria, Chairman and MD: Anurag Bagaria joined Kemwell in 2004 as a second-generation entrepreneur to lead its transformation from a domestic player to a global one. Kemwell has grown from two manufacturing facilities to seven facilities, commenced pharmaceutical R&D services and is now entering the biopharmaceutical development and manufacturing space under his leadership. Anurag has completed his Chemical Engineering from Cornell University and his MBA from Kellogg in the US.
Mr. PerÅke Oldentoft joined the Board of Kemwell India in 2005 and the Board of Kemwell Sweden in 2006. He served as the CEO of Kemwell Sweden from 2006 to 2007. Perake has over 35 years of managerial experience in Life Science in companies like AstraZeneca, Pharmacia, Ferrosan, Gacell and QPharma as CEO and in international sales, marketing, production and product development.
Prof. Dr. Rolf G. Werner was Corporate Senior Vice President of the Corporate Division Biopharmaceuticals at Boehringer Ingelheim GmbH and was responsible for the strategic orientation and the worldwide business of biopharmaceuticals before he retired in 2011.
He obtained his M.Sc. in biology at University of Tübingen in 1971. After his scientific work at the Max-Planck Institute for Molecular Genetics in Berlin he obtained his PhD at University of Tübingen in 1973.
In the same year he joined Boehringer Ingelheim at the Department of Biological Research and has been involved in antibiotic research. After a sabbatical in 1978 at the Massachusetts Institute of Technology in Cambridge, USA, he returned to Boehringer Ingelheim and became Head of Biopharmaceutical Manufacturing.
In 1990 he was appointed as professor at the Faculty of Biology at the University of Tübingen. He is member of the scientific board of the University of Stuttgart and the Fraunhofer Gesellschaft, member of the editorial board of the journal Drug Research and expert agrée for registrations of pharmaceuticals in France.
From 1998 to March 2000 he was head of the Industrial Biopharmaceutical Department at the Boehringer Ingelheim GmbH and therefore responsible for the development and manufacturing of biopharmaceuticals at various sites of Boehringer Ingelheim. According to the importance of this growing business this department became Corporate Division and Prof. Werner was promoted as the Corporate Senior Vice President in March 2000.
S.R. Chandak is the Finance Director of Kemwell. He has been with Kemwell for over 20 years and has a wide experience in finance, accounts, taxation, company law, legal, MIS and active participation in joint ventures. He has completed his B.Com, LLB from Calcutta University and a Diploma in Business Administration from St. Joseph’s College, Bangalore.
Shabbir Anik, Ph.D., MBA
Dr. Anik is an experienced executive in the biotech, pharmaceutical and contract services industry, with expertise in drug development, drug delivery, pharmaceutical technology, operations management, and business leadership. He is currently Sr. VP, Technical Operations at Onyx Pharmaceuticals. He has held several senior management positions including VP, Program Management at Syntex, President, Pharmaceutical Development Services at Patheon, and CEO, Althea Technologies.
He is the founding president and former board member of the non-profit organization EPPIC, and Charter member of TIE, a global organization fostering entrepreneurship. He is also the Chairman of Valgenesis, a software company. He has been an invited lecturer on Technology Transfer in the Berkeley Drug Development course.
Dr. Anik has been credited with 5 issued patents, holds a bachelor of Pharmacy from the University of Bombay’s Institute of Chemical Technology, a Ph.D. in Pharmaceutical Sciences from University of Wisconsin, and an MBA from Santa Clara University.